Themis Medicare Ltd

Themis Medicare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 15 February 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 03 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Themis Medicare Ltd witnessed a robust start to the trading session on 3 Feb 2026, opening with a notable gap up of 9.59%, signalling renewed positive momentum after two consecutive days of decline. This surge outpaced the Pharmaceuticals & Biotechnology sector’s gain of 2.73%, underscoring a distinct shift in market sentiment towards the stock.

Themis Medicare Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.76 today, marking a significant decline in its stock price amidst ongoing downward momentum and underperformance relative to the broader market and sector indices.

Themis Medicare Ltd commenced trading with a significant gap up, opening 6.85% higher than its previous close, signalling a robust start amid positive market sentiment. This upward move outpaced the Pharmaceuticals & Biotechnology sector by 2.86%, marking a notable shift after two consecutive days of decline.

Themis Medicare Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a fresh 52-week low of Rs.77.15 today, marking a significant decline in its stock price amid ongoing downward momentum and underperformance relative to its sector and broader market indices.

Themis Medicare Ltd, a player in the Pharmaceuticals & Biotechnology sector, touched a new 52-week low of Rs.78.7 today, marking a significant decline in its stock price amid ongoing financial headwinds and subdued market performance.

Themis Medicare Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 15 February 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Themis Medicare Ltd’s shares declined sharply to a fresh 52-week low of Rs.79.05 on 21 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed its sector and broader market indices, reflecting persistent financial pressures and subdued sales performance over recent quarters.

Themis Medicare Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.85 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing financial pressures and subdued performance metrics.

Themis Medicare Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a fresh 52-week low of Rs.90.35 today, marking a significant decline in its stock price amid ongoing downward momentum and underperformance relative to its sector and broader market indices.

Themis Medicare Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.93.15 today, marking a significant decline amid a sustained downward trend in its share price over recent sessions.

Themis Medicare Ltd is rated 'Strong Sell' by MarketsMOJO, a rating that was last updated on 15 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Themis Medicare Ltd recorded a robust intraday performance on 07 Jan 2026, surging to a day’s high of Rs 107.4, marking a significant 7.29% increase. This strong upward movement outpaced the Pharmaceuticals & Biotechnology sector and reflected a notable reversal after two days of decline.

Themis Medicare Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 15 Feb 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 January 2026, providing investors with an up-to-date view of the company's performance and outlook.

Themis Medicare, a small-cap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation reflecting ongoing challenges in its financial and operational performance. This shift highlights concerns across multiple analytical parameters, underscoring the company’s current position within a competitive and volatile industry landscape.

Themis Medicare recorded a robust intraday performance on 16 Dec 2025, touching a day’s high of Rs 112.3, reflecting a 7.21% gain from its previous close. This surge stands out amid a broadly negative market backdrop, with the Sensex trading 0.44% lower at 84,841.93 points.

Themis Medicare witnessed a significant gap up at the opening of trading today, registering a gain of 7.21% and signalling a robust start amid a generally subdued market environment. This upward move outpaced the Pharmaceuticals & Biotechnology sector and the broader Sensex, highlighting a distinct positive momentum for the stock.

Themis Medicare, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing financial and technical challenges. This shift highlights the company's current position amid a difficult operating environment and subdued investor sentiment.